RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.